Chu Nantes

Nantes F44093

9 studies enrolling now · 40 studies all time

What they study most

Acute Lung Injury, Acute Myeloid Leukemia (AML), Acute Respiratory Distress Syndrome, Advanced Solid Tumor, Colorectal Cancer, Colorectal Cancer (CRC), Colorectal Neoplasms, Coronavirus Infection, Critical Limb Ischemia, Depressive Disorder, Major, Diabetes Mellitus, EPP

Studies at this site

• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer — Recruiting now
• A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis — Recruiting now
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — Recruiting now
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Recruiting now
• Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) — Recruiting now
• Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) — Recruiting now
• The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis — Recruiting now
• A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma — Running, not enrolling
• A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia — Running, not enrolling
• A Study of Daratumumab — Running, not enrolling
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• First-in-Human Study of ICT01 in Patients With Advanced Cancer — Running, not enrolling
• Global Patient Registry of Inherited Retinal Diseases — Running, not enrolling
• A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health — Completed
• INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP — Completed
• A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension — Completed
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors — Running, not enrolling
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
• A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Completed
• Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer — Running, not enrolling
• A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer — Stopped early
• Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide — Completed
• Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications — Completed
• APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) — Completed
• The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia — Completed
• Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project — Completed
• Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest — Completed
• Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection — Completed
• Diabetic Gastroparesis Study 05 — Stopped early
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma — Completed
• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 — Stopped early
• Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir — Completed
• Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications — Completed
• Epidemiologic Multicenter Study on Mechanical Ventilation Management in Children With Acute Lung Injury — Completed